The tumult of large-scale cuts to federal spending, pullbacks of civil rights protections, and new tariffs getting announced ...

Further information on the abstracts that Roche will present at MDA 2025 can be found below.

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

The first patient has been enrolled in the PROSTATE-IQ trial of ArteraAI, a multimodal artificial intelligence biomarker test ...

Morgan said that every major health insurance provider currently is using AI in some way, both helpful and harmful to ...

CALR mutations occur in about 20% of patients with primary and post-essential thrombocythemia myelofibrosis, as per the study ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.

On St Patrick's Day, investors hope for the luck of the Irish ahead of Opthea's key trial update and Imricor's ambitious fund ...

The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among physicians about cost-driven mandates and the autonomy to choose the best therapies ...

Industry leaders say government failed to protect Thomas Cooper from dying in a hyperbaric chamber fire at the Oxford Center ...

While we're not short of divisive topics in 2025, there are valid reasons as to why we're turning to chatbots for emotional ...